Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...105106107108109110111112113114115...123124»
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Lenvatinib in differentiated thyroid carcinoma: the Italian experience. (Pubmed Central) -  Feb 1, 2020   
    Real-life data, obtained by case reports and retrospective studies, are equally important to increase the knowledge about this drug and improve the clinical management. No abstract available
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Clinical, Journal:  Management of one patient with oligoprogressive thyroid cancer during treatment with lenvatinib. (Pubmed Central) -  Feb 1, 2020   
    We found that the application of local ablative therapy in oligoprogressive disease prolonged the progression-free survival and thus extended the time to therapy interruption. However, the optimal care for TKI-treated oligoprogressive cancers remains unclear and needs to be investigated in prospective trials.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) -  Jan 31, 2020   
    P1,  N=28, Recruiting, 
    In conclusion, GdCho-Len-PET increased the diagnostic efficacy and had a significant effect on survival for patients with lung cancer, and may therefore serve as a reliable method for human cancer diagnosis. Trial completion date: Apr 2020 --> Apr 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    GENOMIC LANDSCAPE AND IMMUNE CHARACTERISTICS OF PAIRED PRIMARY AND RECURRENT HEPATOCELLULAR CARCINOMA () -  Jan 28, 2020 - Abstract #DDW2020DDW_1845;    
    Our data provide evidence for the need of different immune therapy approach for specific recurrence type. For true recurrence type, the higher immune cell infiltration with higher expression of immune checkpoint molecules in recurrent tumors indicates that immune checkpoint inhibitors might be a promising treatment to prevent and treat this kind of recurrence
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Clinical outcome of lenvatinib therapy in Japanese patients with unresectable hepatocellular carcinoma ~a nationwide multicenter study~ (ePoster Area) -  Jan 27, 2020 - Abstract #EASLHCC2020EASL_HCC_116;    
    For true recurrence type, the higher immune cell infiltration with higher expression of immune checkpoint molecules in recurrent tumors indicates that immune checkpoint inhibitors might be a promising treatment to prevent and treat this kind of recurrence Clinical outcome of lenvatinib therapy for Japanese patients with u-HCC in real world practice was similar to the phase 3 clinical trial, even though the Japanese patients were older and had lower bodyweight.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Efficiency and Toxicity of Lenvatinib in Advanced HCC in Later Treatment Lines (Room A2) -  Jan 25, 2020 - Abstract #DKK2020DKK_2187;    
    Currently sorafenib and lenvatinib are options for first line treatment with regorafenib, cabozantinib and ramucirumab (if alpha fetoprotein > 400 ng / ml) as second-line treatment choices... Lenvatinib is a promising agent for treating advanced HCC in later treatment lines and revealed a tolerable toxicity profile.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Pathological Features of Immune-Mediated Hepatitis Caused by Immune Checkpoint Inhibitors and Multiple Receptor Tyrosine Kinases (LACC West Exhibit Hall A, Poster Board Number: 130) -  Jan 24, 2020 - Abstract #USCAP2020USCAP_2642;    
    Oral small molecule inhibitors of multiple receptor tyrosine kinases (TKIs) such as sorafenib and lenvatinib have been used as first-line treatment in patients with advanced HCC. Combination of ICIs and TKIs may cause overlapping hepatocyte injury, which is much worse than the IMH caused by monotherapy ICIs.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Adverse events:  Wound healing complications with lenvatinib identified in a pharmacovigilance database. (Pubmed Central) -  Jan 21, 2020   
    FAERS case-level evidence suggests that lenvatinib may have contributed to wound healing complications based on temporality and biologic plausibility. Healthcare professionals should be aware of this safety risk to facilitate prompt recognition and risk mitigation.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date, Metastases:  Lenvatinib and Pembrolizumab in People with Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers (clinicaltrials.gov) -  Jan 19, 2020   
    P2,  N=64, Not yet recruiting, 
    This case emphasizes that it is necessary to observe the patient's respiratory condition and to perform imaging examinations to monitor for adverse events during TKI treatment. Initiation date: Dec 2019 --> Mar 2020